Research ArticleOriginal Article
Open Access

Pattern of drugs use and association with anti-mutated citrullinated vimentin antibody in rheumatoid arthritis

Mohammad-Ayman A. Safi and Omar A. Fathaldin
Saudi Medical Journal March 2015, 36 (3) 316-323; DOI: https://doi.org/10.15537/smj.2015.3.10208

References

  1. ↵
    1. Scott DL,
    2. Wolfe F,
    3. Huizinga TW
    (2010) Rheumatoid arthritis. Lancet 376:1094–108.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Smolen JS,
    2. van der Heijde D,
    3. Machold KP,
    4. Aletaha D,
    5. Landewé R
    (2014) Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 73:3–5.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Bijlsma JW,
    2. Hoes JN,
    3. Van Everdingen AA,
    4. Verstappen SM,
    5. Jacobs JW
    (2006) Are glucocorticoids DMARDs? Ann N Y Acad Sci 1069:268–274.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Task Force for the Diagnosis and Management of Syncope;European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS),
    2. Moya A,
    3. et al.
    (2009) Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 30:2631–2671.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Gramling A,
    2. O’Dell JR
    (2012) Initial management of rheumatoid arthritis. Rheum Dis Clin North Am 38:311–325.
    OpenUrlPubMed
  6. ↵
    1. Swierkot J,
    2. Szechiński J
    (2006) Methotrexate in rheumatoid arthritis. Pharmacol Rep 58:473–492.
    OpenUrlPubMedWeb of Science
  7. ↵
    1. Rau R,
    2. Herborn G
    (2004) Benefit and risk of methotrexate treatment inrheumatoid arthritis. Clin Exp Rheumatol 22(Suppl. 35):S83–S94.
    OpenUrlPubMedWeb of Science
  8. ↵
    1. Wasserman AM
    (2011) Diagnosis and management of rheumatoid arthritis. Am Fam Physician 84:1245–1252.
    OpenUrlPubMed
    1. Deighton C,
    2. O’Mahony R,
    3. Tosh J,
    4. Turner C,
    5. Rudolf M,
    6. Guideline Development Group
    (2009) Management of rheumatoid arthritis: summary of NICE guidance. BMJ 338:b702.
    OpenUrlFREE Full Text
  10. ↵
    1. DiPiro JT,
    2. Talbert RT,
    3. Yee GC,
    4. Matzke GR,
    5. Wells BG,
    6. Posey LM
    (2008) Pharmacotherapy: a pathophysiologic approach (McGraw-Hill, New York (NY)), 7th ed.
  11. ↵
    1. Singh JA,
    2. Furst DE,
    3. Bharat A,
    4. Curtis JR,
    5. Kavanaugh AF,
    6. Kremer JM,
    7. et al.
    (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care & Research 64:625–639.
    OpenUrl
  12. ↵
    1. Smolen JS,
    2. Landewe R,
    3. Breedveld FC,
    4. Dougados M,
    5. Emery P,
    6. Gaujoux-Viala C,
    7. et al.
    (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Shea B,
    2. Swinden MV,
    3. Tanjong Ghogomu E,
    4. Ortiz Z,
    5. Katchamart W,
    6. Rader T,
    7. et al.
    (2013) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 5:CD000951.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Lie E,
    2. van der Heijde D,
    3. Uhlig T,
    4. Mikkelsen K,
    5. Kalstad S,
    6. Kaufmann C,
    7. et al.
    (2011) Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register. Ann Rheum Dis 70:2103–2110.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.
    (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Al-Bishri J,
    2. Attar S,
    3. Bassuni N,
    4. Al-Nofaiey Y,
    5. Qutbuddeen H,
    6. Al-Harthi S,
    7. et al.
    (2013) Comorbidity profile among patients with rheumatoid arthritis and the impact on prescriptions trend. Clin Med Insights Arthritis Musculoskelet Disord 6:11–18.
    OpenUrl
  17. ↵
    1. Safi MA,
    2. Houssien DA,
    3. Scott DL
    (2012) Disease activity and anti-cyclic citrullinated peptide (anti-CCP) antibody in Saudi RF-ve rheumatoid arthritis patients. Journal of King Abdulaziz University Medical Sciences 19:3–20.
    OpenUrl
  18. ↵
    1. Visser K,
    2. van der Heijde DM
    (2009) Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 27:1017–1025.
    OpenUrlPubMed
  19. ↵
    1. Visser K,
    2. Katchamart W,
    3. Loza E,
    4. Martinez-Lopez JA,
    5. Salliot C,
    6. Trudeau J,
    7. et al.
    (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68:1086–1093.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Antohe JL,
    2. Bili A,
    3. Sartorius JA,
    4. Kirchner HL,
    5. Morris SJ,
    6. Dancea S,
    7. et al.
    (2012) Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy. Arthritis Care Res (Hoboken) 64:215–221.
    OpenUrl
  21. ↵
    1. Kim SY,
    2. Yoo CG,
    3. Lee CT,
    4. Chung HS,
    5. Kim YW,
    6. Han SK,
    7. et al.
    (2011) Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease. J Korean Med Sci 26:264–267.
    OpenUrlPubMed
  22. ↵
    1. Ledwich LJ,
    2. Clarke K
    (2009) Screening and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients in an urban multispecialty practice. J Clin Rheumatol 15:61–64.
    OpenUrlPubMed
  23. ↵
    1. Heberlein I,
    2. Demary W,
    3. Bloching H,
    4. Braun J,
    5. Buttgereit F,
    6. Dreher R,
    7. et al.
    (2011) [Diagnosis and treatment of osteoporosis and rheumatoid arthritis in accordance with German guidelines. Results of a survey of patients, primary care physicians and rheumatologists]. Z Rheumatol 70:592–601, German.
    OpenUrlPubMed
  24. ↵
    1. Panoulas VF,
    2. Douglas KM,
    3. Stavropoulos-Kalinoglou A,
    4. Metsios GS,
    5. Nightingale P,
    6. Kita MD,
    7. et al.
    (2008) Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 47:72–75.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Situnayake RD,
    2. Kitas G
    (1997) Dyslipidemia and rheumatoid arthritis. Ann Rheum Dis 56:341–342.
    OpenUrlFREE Full Text
  26. ↵
    1. Ettinger WH,
    2. Klinefelter HF,
    3. Kwiterovitch PO
    (1987) Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis 63:167–172.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Shea B,
    2. Swinden MV,
    3. Tanjong Ghogomu E,
    4. Ortiz Z,
    5. Katchamart W,
    6. Rader T,
    7. Bombardier C,
    8. Wells GA,
    9. Tugwell P
    (2013) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Syst Rev 5:CD000951.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section